DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Conditions
Anus | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast | Urinary Bladder
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
- Ages18 years and older
- GenderBoth
- Trial withSouthwest Oncology Group (SWOG)
- Start Date06/13/2022
- End Date08/31/2021
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Aarti Bhatia, MD, MPH
- Agatha Hecht
- Alessia Donadio, MD
- Andrea Brennan
- Andrea Martelli
- Daniel P. Petrylak, MD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Joseph Kim, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Lynn Cochran
- Madeline Santiago
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Michael Hurwitz, PhD, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Sarah Carlson
- Stacey Stein, MD
- Su Hsien Lim, MD
- Victor Chang, MD
- Vidya Brown
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Last Updated06/15/2022
- Study HIC#2000020739